Emma Morris

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)
    Emma Morris
    Department of Haematology, University College London Hospitals, 98 Chenies Mews, London W1E6HX, United Kingdom
    Transfus Apher Sci 32:73-83. 2005
  2. ncbi request reprint Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
    Emma C Morris
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
    Blood 102:404-6. 2003
  3. ncbi request reprint Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
    Emma Morris
    Department of Haematology, Royal Free and University College Hospitals Medical School, 98 Chenies Mews, London WC1E 6HX, United Kingdom
    Blood 104:3865-71. 2004
  4. ncbi request reprint Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma
    Emma C Morris
    Department of Haematology, Royal Free and University College London Hospitals Medical School, London WC1E 6HX, UK
    Best Pract Res Clin Haematol 18:129-42. 2005
  5. doi request reprint Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation
    Guillermo Orti
    Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
    Transplantation 88:1312-8. 2009
  6. doi request reprint HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
    Adam J Mead
    Department of Haematology, University College London UCL Medical School, London, United Kingdom
    Blood 115:5147-53. 2010
  7. ncbi request reprint Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    Karl S Peggs
    Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
    Blood 103:1548-56. 2004
  8. ncbi request reprint Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure
    Jaimal Kothari
    Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
    Br J Haematol 165:334-40. 2014
  9. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
  10. doi request reprint T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma
    Kirsty J Thomson
    Department of Haematology, University College Hospital, London, UK
    J Clin Oncol 28:3695-700. 2010

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)
    Emma Morris
    Department of Haematology, University College London Hospitals, 98 Chenies Mews, London W1E6HX, United Kingdom
    Transfus Apher Sci 32:73-83. 2005
    ..Patients with relapsed LG-NHL and CLL achieve excellent PFS with extremely low TRM and GVHD, even when matched family donors are unavailable...
  2. ncbi request reprint Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
    Emma C Morris
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
    Blood 102:404-6. 2003
    ..Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P =.005), and median absolute CD4 counts higher than 200 x 106/L were delayed until 9 months after transplantation...
  3. ncbi request reprint Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
    Emma Morris
    Department of Haematology, Royal Free and University College Hospitals Medical School, 98 Chenies Mews, London WC1E 6HX, United Kingdom
    Blood 104:3865-71. 2004
    ..Patients who experienced relapses of LG-NHL and chronic lymphocytic leukemia (CLL) achieved excellent PFS with extremely low TRM and GVHD, even when matched related donors were unavailable...
  4. ncbi request reprint Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma
    Emma C Morris
    Department of Haematology, Royal Free and University College London Hospitals Medical School, London WC1E 6HX, UK
    Best Pract Res Clin Haematol 18:129-42. 2005
    ..Here we will discuss the rationale behind reduced intensity transplantation (RIT), the development of the regimens currently adopted in clinical practice and review the published literature on RIT for indolent NHL...
  5. doi request reprint Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation
    Guillermo Orti
    Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
    Transplantation 88:1312-8. 2009
    ..The drawback of DLI is the risk of graft-versus-host disease (GVHD). In this phase I study, we examined the potential of highly extensive CD8 depletion of DLI as a means of improving its safety profile...
  6. doi request reprint HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
    Adam J Mead
    Department of Haematology, University College London UCL Medical School, London, United Kingdom
    Blood 115:5147-53. 2010
    ..44). Mismatch occurred at the antigenic level in 40 cases. The outcome in these cases did not differ significantly from the rest of the cohort. We conclude that RIT using HLA-mismatched grafts is a viable option using FMC conditioning...
  7. ncbi request reprint Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    Karl S Peggs
    Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
    Blood 103:1548-56. 2004
    ....
  8. ncbi request reprint Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure
    Jaimal Kothari
    Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
    Br J Haematol 165:334-40. 2014
    ..Our data shows that BEAM ASCT can be a highly effective treatment in patients with FL early in the disease course, and that a proportion of patients experience prolonged disease-free survival and may be cured...
  9. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
    ..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
  10. doi request reprint T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma
    Kirsty J Thomson
    Department of Haematology, University College Hospital, London, UK
    J Clin Oncol 28:3695-700. 2010
    ..Thus, reduced-intensity conditioning regimens are being explored...
  11. ncbi request reprint Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
    Karl S Peggs
    Department of Haematology, Royal Free and University College London, UK
    Lancet 365:1934-41. 2005
    ..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
  12. doi request reprint Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma
    Jonathan R Lambert
    Department of Haematology, University College London Cancer Institute, London, UK
    Blood 115:2763-8. 2010
    ....
  13. ncbi request reprint Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen
    Karl S Peggs
    Blood 99:4642-3; author reply 4643-4. 2002
  14. ncbi request reprint Reversal of severe cholestasis caused by chronic graft-versus-host disease with the MARS liver-support device
    Sambit Sen
    Transplantation 75:1766-7. 2003
  15. pmc A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection
    Emma C Morris
    Department of Immunology, Imperial College, Du Cane Road, London W12 0NN, United Kingdom
    Proc Natl Acad Sci U S A 102:7934-9. 2005
    ..The data demonstrate in vivo synergy between T cell antigen receptor-transduced CD4(+) and CD8(+) T cells specific for the same epitope resulting in long-term tumor protection...
  16. ncbi request reprint Monoclonal T-cell receptors: new reagents for cancer therapy
    Hans J Stauss
    Department of Immunology and Molecular Pathology, University College London, Hampstead Campus, Royal Free Hospital, London, UK
    Mol Ther 15:1744-50. 2007
    ..Both, expression of only the introduced TCR chains and the production of naïve T cells may be possible in the future by TCR gene transfer into stem cells...
  17. ncbi request reprint Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia
    Emma C Morris
    Department of Haematology, Great Ormond Street Hospital for Children, London, UK
    Br J Haematol 120:787-9. 2003
    ..02) and time from diagnosis to second CNS relapse (longer time was better, P = 0.004). Prognosis after second CNS relapse is extremely poor, and palliative therapy is appropriate...